10x Genomics (TXG) Change in Acquisitions & Divestments (2022 - 2026)

10x Genomics (TXG) has 5 years of Change in Acquisitions & Divestments data on file, last reported at $25.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments changed N/A year-over-year to $25.0 million; the trailing twelve-month figure through Mar 2026 stood at $150.2 million (up 495.7% YoY), and the FY2025 full-year result was $125.2 million, up 385.61% from the prior year.
• Change in Acquisitions & Divestments slipped to $25.0 million in Q1 2026, from $125.2 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $125.2 million in Q4 2025 to a low of -$50.0 million in Q3 2025.
• A 5-year average of $19.2 million and a median of $16.3 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• Peak annual rise in Change in Acquisitions & Divestments reached 1557.28% in 2025, while the deepest fall reached 18550.18% in 2025.
• Tracing TXG's Change in Acquisitions & Divestments over 5 years: stood at $31.9 million in 2022, then sank by 141.68% to -$13.3 million in 2023, then jumped by 264.71% to $21.9 million in 2024, then soared by 471.01% to $125.2 million in 2025, then plunged by 80.03% to $25.0 million in 2026.
• Business Quant data shows TXG's Change in Acquisitions & Divestments at $25.0 million in Q1 2026, $125.2 million in Q4 2025, and -$50.0 million in Q3 2025.